Literature DB >> 6132566

Pharmacokinetics and pharmacodynamics of vecuronium (ORG NC45) and pancuronium in anesthetized humans.

R Cronnelly, D M Fisher, R D Miller, P Gencarelli, L Nguyen-Gruenke, N Castagnoli.   

Abstract

The pharmacokinetics and pharmacodynamics of vecuronium (25-50 micrograms/kg) and pancuronium (25-50 micrograms/kg) were determined in nine ASA class I or II patients anesthetized with nitrous oxide and halothane. Force of thumb adduction in response to supramaximal stimulation of the ulnar nerve was quantified and recorded. Serum concentrations of the muscle relaxants were determined for eight hours after their administration using a mass spectrometry assay. Data were analyzed by nonlinear regression and fit to a three-compartment pharmacokinetic model and a four-compartment pharmacodynamic model. Vecuronium had a more rapid clearance (5.2 +/- 0.7 ml X kg-1 X min-1; mean +/- SD) and a shorter elimination half-life (71 +/- 20 min) as compared with pancuronium (1.8 +/- 0.4 ml X kg-1 X min-1; 140 +/- 25 min). No other pharmacokinetic differences were found between the drugs. Pharmacodynamic analysis showed that the plasma concentration at steady state which produced a 50% neuromuscular blockade (Cpss 50) was similar for vecuronium and pancuronium. The authors conclude that the drugs are equivalent in their onset and potency; however, the more rapid clearance and shorter elimination half-life for vecuronium provides a kinetic basis for its shorter duration of neuromuscular blockade as compared with pancuronium.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6132566     DOI: 10.1097/00000542-198305000-00002

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  16 in total

1.  Relationship between train-of-four ratio and first-twitch depression during neuromuscular blockade: a pharmacokinetic/dynamic explanation.

Authors:  R R Bartkowski; R H Epstein
Journal:  J Pharmacokinet Biopharm       Date:  1990-08

Review 2.  Clinical pharmacokinetics of neuromuscular blocking drugs.

Authors:  S Agoston; R H Vandenbrom; J M Wierda
Journal:  Clin Pharmacokinet       Date:  1992-02       Impact factor: 6.447

Review 3.  A simulation of neuromuscular function and heart rate during induction, maintenance, and reversal of neuromuscular blockade.

Authors:  R R Jaklitsch; D R Westenskow
Journal:  J Clin Monit       Date:  1990-01

Review 4.  Clinical pharmacokinetics of neuromuscular relaxants in pregnancy.

Authors:  J Guay; Y Grenier; F Varin
Journal:  Clin Pharmacokinet       Date:  1998-06       Impact factor: 6.447

Review 5.  Neuromuscular transmission and its pharmacological blockade. Part 4: Use of relaxants in paediatric and elderly patients, in obstetrics, and in the intensive care unit.

Authors:  L H Booij
Journal:  Pharm World Sci       Date:  1997-02

Review 6.  Intravenous anaesthetic agents. Pharmacokinetic-pharmacodynamic relationships.

Authors:  B N Swerdlow; F O Holley
Journal:  Clin Pharmacokinet       Date:  1987-02       Impact factor: 6.447

7.  Simulation of the kinetics of neuromuscular block: implications for speed of onset.

Authors:  James P Dilger
Journal:  Anesth Analg       Date:  2013-03-01       Impact factor: 5.108

8.  Pharmacokinetics and pharmacodynamics of vecuronium bromide.

Authors:  T Nomura
Journal:  J Anesth       Date:  1992-01       Impact factor: 2.078

9.  Pharmacokinetic and pharmacodynamic modelling with pancuronium.

Authors:  M A Evans; C A Shanks; K F Brown; E J Triggs
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

Review 10.  New intravenous anaesthetics and neuromuscular blocking drugs. A review of their properties and clinical use.

Authors:  C S Reilly; W S Nimmo
Journal:  Drugs       Date:  1987-07       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.